Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Tam, Constantine S., Trotman, Judith, Opat, Stephen, Burger, Jan A., Cull, Gavin, Gottlieb, David, Harrup, Rosemary, Johnston, Patrick B., Marlton, Paula, Munoz, Javier, Seymour, John F., Simpson, David, Tedeschi, Alessandra, Elstrom, Rebecca, Yu, Yiling, Tang, Zhiyu, Han, Lynn, Huang, Jane, Novotny, William, Wang, Lai, Roberts, Andrew W.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2019
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742923/
https://ncbi.nlm.nih.gov/pubmed/31340982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001160
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍